Exonic develops artificial intelligence solutions specifically tailored for precision gene therapy applications. The platform leverages advanced machine learning to optimize therapeutic design and delivery mechanisms. This focus accelerates the development of highly targeted and effective genetic treatments for complex diseases.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The discovery of effective cancer therapeutics is hindered by long development timelines, high costs, and limited exploration of novel chemical space, resulting in low preclinical success rates and delayed patient access to new treatments.
Solution
Exonic operates an AI‑enabled crowdsourcing platform that generates candidate molecules for oncology indications and routes them through automated, cell‑based validation assays. Machine‑learning models propose chemically diverse structures, which are then synthesized in silico and evaluated in living‑cell screens to assess potency, toxicity, and mechanism of action. Validated hits are compiled into a preclinical data repository that pharmaceutical partners can query for lead optimization. Contributors receive a fixed monetary reward for successful submissions, creating a scalable pipeline of externally sourced ideas that accelerate early‑stage drug development.
Target Audience
Primary customers are oncology R&D divisions of pharmaceutical companies and biotech firms that require early‑stage, experimentally validated compound leads, as well as academic laboratories seeking to monetize novel therapeutic concepts.
Features
- Generative AI engine that designs oncology‑focused small‑molecule structures based on target biology and medicinal chemistry constraints
- Web‑based crowdsourcing portal allowing researchers to submit, iterate, and track compound proposals
- Integrated in silico synthesis planning to assess synthetic feasibility before experimental testing
- High‑throughput living‑cell assay platform that measures activity, cytotoxicity, and selectivity across multiple cancer cell lines
- Secure, HIPAA‑compliant data storage with versioned compound records and assay results
- Automated reward distribution ($5,000 per validated hit) managed through a blockchain‑backed escrow system
- Analytics dashboard providing partners with hit‑rate metrics, structure‑activity trends, and downloadable data packages via RESTful API